Pfizer v. Sinotherapeutics: Tofacitinib Patent Dispute Dismissed Without Prejudice
Pfizer and four co-plaintiffs sued Sinotherapeutics in the District of Delaware over three patents protecting tofacitinib citrate and its oral sustained-release formulations. After 692 days, the parties jointly stipulated to dismiss all claims and counterclaims without prejudice, with each side bearing its own costs.
Pfizer’s Tofacitinib Patents Face Sinotherapeutics in Delaware ANDA Battle
On 11 November 2022, Pfizer Inc. together with co-plaintiffs PF Prism C.V., C.P. Pharmaceuticals International C.V., PBG Puerto Rico LLC, and PF PRISM IMB B.V. filed suit against Sinotherapeutics Inc. in the U.S. District Court for the District of Delaware (Case No. 1:22-cv-01484) before Judge Gregory B. Williams. The complaint asserted infringement of three patents — USRE041783E, US6965027B2, and US11253523B2 — covering crystalline tofacitinib citrate and oral sustained-release dosage forms of the JAK inhibitor marketed as Xeljanz.
On 3 October 2024, the parties filed a joint stipulation of dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii), dismissing all claims and counterclaims without prejudice. The stipulation also resolved a companion action (1:21-cv-01427-GBW). Protective orders entered by the court remain in force, and the District of Delaware retains jurisdiction to enforce the underlying settlement agreement. Each party bears its own costs and fees, and both sides expressly waived any right of appeal.
At 692 days, the duration suggests the parties engaged substantively — likely through claim construction, expert proceedings, or settlement negotiations — before reaching resolution. The without-prejudice dismissal, combined with the court retaining settlement-enforcement jurisdiction, is consistent with a negotiated commercial resolution rather than a concession on the merits. The precise terms of the underlying settlement remain confidential and are not reflected in the public record.
Filing to Dismissed without Prejudice in 692 days
692 days — above the median for ANDA/pharma patent cases in Delaware, suggesting substantive engagement before resolution
Dismissed without prejudice: what the stipulated order means for both parties
Rule 41 stipulated dismissal — no merits adjudication
Under Fed. R. Civ. P. 41(a)(1)(A)(ii), a case may be dismissed by joint stipulation of all parties who have appeared, without a court order. This mechanism carries no finding of infringement, validity, or enforceability. Because the dismissal is without prejudice, the claims are not extinguished — Pfizer could theoretically refile if a future trigger arises, though the settlement agreement likely governs any such scenario.
No merits rulingWithout prejudice: claims are not permanently barred
A dismissal without prejudice means neither party obtained a final judgment on the patents’ validity or infringement. This contrasts with a with-prejudice dismissal, which would bar re-litigation. The public record is silent on whether the underlying settlement contains any licence, covenant not to sue, or market-entry provisions — those terms, if any, are confidential. The retention of court jurisdiction suggests the parties formalised their resolution in a separate settlement agreement.
No res judicata effectPfizer’s patents remain unchallenged on the merits
Pfizer’s three tofacitinib patents — USRE041783E, US6965027B2, and US11253523B2 — exit this litigation with no adverse validity or infringement finding. Their enforceability is formally intact. If the settlement includes a licence or entry date for Sinotherapeutics, Pfizer will have converted litigation risk into a controlled commercial outcome, a common strategy in Hatch-Waxman disputes.
Patents legally intactSinotherapeutics avoids an adverse judgment
Sinotherapeutics avoided a final infringement or validity ruling that could have blocked its tofacitinib product entirely. The without-prejudice posture and waiver of appeal rights by both sides, combined with the court retaining settlement jurisdiction, is consistent with Sinotherapeutics having negotiated an agreed-upon path — possibly a delayed or licensed market entry. The absence of a cost award also suggests neither side claimed a clear litigation win.
No infringement findingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | Global pharmaceutical company — holder of USRE041783E, US6965027B2, and US11253523B2 covering tofacitinibSearch in Eureka ↗ |
| Co-Plaintiff | PF Prism C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | C.P. Pharmaceuticals International C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Pbg Puerto Rico, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | PF Prism Ibm C.V. | Individual | Search in Eureka ↗ |
| Defendant | Sinotherapeutics, Inc. | Company | Sinotherapeutics Inc. — pharmaceutical company seeking to market a generic tofacitinib citrate productSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Richard Charles Weinblatt | Attorney | Counsel for Sinotherapeutics, Inc.Search in Eureka ↗ |
| Defendant counsel | Shashank S. Upadhye | Attorney | Counsel for Sinotherapeutics, Inc.Search in Eureka ↗ |
| Defendant counsel | Yixin H. Tang | Attorney | Counsel for Sinotherapeutics, Inc.Search in Eureka ↗ |
| Defendant law firm | Stamoulis & Weinblatt LLC | Law Firm | Representing Sinotherapeutics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s language is precise: all claims and counterclaims are dismissed without prejudice under Rule 41(a)(1)(A)(ii), with no merit-based findings on infringement or validity. The explicit retention of court jurisdiction to enforce the settlement agreement is legally significant — it transforms a procedural dismissal into an enforceable consent framework. The mutual waiver of appeal rights and symmetric cost-bearing clause suggest neither party conceded the other’s position, consistent with a negotiated commercial resolution whose specific terms remain outside the public record.
USRE041783E, US6965027B2 & US11253523B2 — Tofacitinib Citrate and Oral SR Forms
The three asserted patents collectively protect tofacitinib citrate — the active ingredient in Pfizer’s Xeljanz — at multiple levels of the product chain. USRE041783E is a reissue patent, meaning it underwent a second USPTO examination, which can broaden or clarify original claims and may reinforce validity arguments in litigation. US6965027B2 covers the core pyrrolo[2,3-d]pyrimidine chemical entity, while US11253523B2, with an application date traceable to US16/817689, protects oral sustained-release dosage forms — the specific formulation technology challenged by Sinotherapeutics’ ANDA filing.
Tofacitinib is a first-generation oral JAK inhibitor with significant market value in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Pfizer’s three-patent stack — compound, salt form, and sustained-release formulation — represents a classic layered exclusivity strategy designed to extend effective market protection well beyond any single patent expiry. For competitors developing generic or biosimilar tofacitinib products, each patent layer requires independent clearance, and the reissue status of USRE041783E demands particular scrutiny of its prosecution history and claim scope.
Should you run an FTO against USRE041783E, US6965027B2, and US11253523B2?
Any company developing a generic tofacitinib citrate product, an oral JAK inhibitor sustained-release formulation, or a related pyrrolo[2,3-d]pyrimidine compound should treat these three patents as a priority FTO target. The without-prejudice dismissal in this case does not extinguish the patents or limit their enforceability against third parties — Pfizer retains full rights to assert them against any new ANDA filer or innovator working in the tofacitinib space. R&D teams exploring JAK inhibitor formulation technology should evaluate whether their candidate falls within the claim scope of US11253523B2 in particular.
PatSnap Eureka’s FTO Search Agent can map your compound or formulation against the full claim trees of USRE041783E, US6965027B2, and US11253523B2 simultaneously. It surfaces related family members, identifies prosecution history estoppel, and flags active Paragraph IV certifications — giving your IP and regulatory teams a consolidated risk picture before committing to clinical or manufacturing investment. Use the Eureka litigation monitor to track any new Pfizer enforcement actions in the tofacitinib space as additional ANDA filers emerge.
Run a freedom-to-operate analysis on USRE041783E to assess your product’s exposure
Run FTO in Eureka →Similar Tofacitinib and JAK Inhibitor Patent Cases in Delaware
Cases involving tofacitinib citrate patents and oral JAK inhibitor formulation disputes filed in the District of Delaware under the Hatch-Waxman framework.
What this case signals for the tofacitinib and JAK inhibitor IP landscape
Pfizer’s multi-plaintiff, multi-patent strategy in Delaware reflects the Hatch-Waxman playbook — and the resolution carries lessons for generic challengers and branded defenders alike.
Multi-patent stacking amplifies settlement leverage in Hatch-Waxman disputes
Pfizer asserted three patents spanning the active compound, its crystalline salt form, and oral sustained-release formulations. This layered approach forces a generic challenger to invalidate or design around each independently — raising the cost and uncertainty of litigation and increasing pressure to settle on branded-company terms.
Delaware court’s retained jurisdiction signals a structured settlement, not abandonment
When a district court retains jurisdiction to enforce a settlement agreement post-dismissal, it signals the parties reached a substantive commercial arrangement — likely including entry-date provisions, licensing terms, or royalty obligations. Generic entrants should treat this as a market-access signal, not a free-entry signal, for tofacitinib sustained-release formulations.
Pfizer v Sinotherapeutics — key questions answered
Pfizer asserted three patents: USRE041783E (reissue patent covering crystalline tofacitinib citrate), US6965027B2 (covering the pyrrolo[2,3-d]pyrimidine compound), and US11253523B2 (covering tofacitinib oral sustained-release dosage forms). The case was filed in the District of Delaware on 11 November 2022.
The parties filed a joint stipulation of dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii) on 3 October 2024. A without-prejudice dismissal carries no merit-based finding on validity or infringement and is commonly used to implement a negotiated settlement. The District of Delaware retained jurisdiction to enforce the underlying settlement agreement, suggesting a formal commercial resolution was reached.
No. A dismissal without prejudice under Rule 41 carries no finding on patent validity or infringement. All three patents — USRE041783E, US6965027B2, and US11253523B2 — remain legally valid and enforceable. Pfizer retains the right to assert them against other parties, including future ANDA filers seeking to market generic tofacitinib products.
A reissue patent has undergone a second USPTO examination, which can clarify or broaden original claims. This process may strengthen the presumption of validity in litigation, as the patent has withstood additional scrutiny. Challengers must account for this when assessing invalidity arguments or IPR petition strategies targeting tofacitinib citrate patents.
When a district court retains jurisdiction after a stipulated dismissal, it can enforce the terms of the parties’ settlement agreement if a dispute arises. This is common in Hatch-Waxman cases where the settlement includes market-entry dates, licensing provisions, or other commercial terms. It signals the dismissal is backed by a substantive agreement, not merely an abandonment of the litigation.
PatSnap Eureka searches patents and litigation data to answer instantly.